Bedaquiline, Delamanid, Moxifloxacin — Competitive Intelligence Brief

Bedaquiline, Delamanid, Moxifloxacin (Bedaquiline, Delamanid, Moxifloxacin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antitubercular. Area: Infectious Disease.

phase 2 Antitubercular ATP synthase Infectious Disease Small molecule

Target snapshot

Bedaquiline, Delamanid, Moxifloxacin (Bedaquiline, Delamanid, Moxifloxacin) — LigaChem Biosciences, Inc.. Inhibits Mycobacterium tuberculosis ATP synthase

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Bedaquiline, Delamanid, Moxifloxacin TARGET	Bedaquiline, Delamanid, Moxifloxacin	LigaChem Biosciences, Inc.	phase 2	Antitubercular	ATP synthase
Bedaquiline (B)	Bedaquiline (B)	Shenzhen Third People's Hospital	marketed	ATP synthase inhibitor	Mycobacterial ATP synthase
BPaL(M) regimen	BPaL(M) regimen	Asan Medical Center	marketed	Anti-tuberculosis combination regimen	Multiple: ATP synthase (bedaquiline), cell wall synthesis (pretomanid), ribosomal protein synthesis (linezolid), DNA gyrase (moxifloxacin)
BE-PEP Bedaquiline	BE-PEP Bedaquiline	Institute of Tropical Medicine, Belgium	phase 3	ATP synthase inhibitor	Mycobacterial ATP synthase
Bedaquiline Oral Tablet	Bedaquiline Oral Tablet	Wits Health Consortium (Pty) Ltd	phase 3	ATP synthase inhibitor	Mycobacterial ATP synthase
BPaL	BPaL	Otsuka Pharmaceutical Development & Commercialization, Inc.	phase 3	Antituberculous combination therapy	Mycobacterial ATP synthase (bedaquiline), mycobacterial DNA/proteins (pretomanid), bacterial ribosome (linezolid)
Tuberculosis treatment	Tuberculosis treatment	National Institute of Allergy and Infectious Diseases (NIAID)	phase 3	Antitubercular	InhA

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antitubercular class)

1. All India Institute of Medical Sciences · 2 drugs in this class
2. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
3. LigaChem Biosciences, Inc. · 1 drug in this class
4. Nantes University Hospital · 1 drug in this class
5. National Institute of Allergy and Infectious Diseases (NIAID) · 1 drug in this class
6. The Aurum Institute NPC · 1 drug in this class